Evommune CSO sells 1,488 shares after option exercise

Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel executed an option exercise and related share sale in Evommune (EVMN) stock.

Rhea-AI Filing Summary

Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel executed an option exercise and related share sale in Evommune (EVMN) stock. On June 22, 2026, he exercised 1,488 employee stock options at $3.84 per share and sold 1,488 common shares in an open-market transaction at $22.50 per share. Following these transactions, he directly holds 46,403 shares of common stock and 27,842 employee stock options, which are scheduled to vest over time and expire on May 11, 2033. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating the timing was set in advance.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,488 shares ($28K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Patel Jeegar Pravinkumar

Role Chief Scientific Officer

Sold 1,488 shs ($33K)

Approx. gross sale proceeds $33K

Approx. exercise cost $6K

Approx. pre-tax spread $28K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	1,488	$0.00	$0.00
Exercise	Common Stock	1,488	$3.84	$6K
Sale	Common Stock	1,488	$22.50	$33K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 27,842 contracts (Direct); Common Stock — 46,403 shares (Direct)

Footnotes (2)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
2. F2. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Shares sold: 1,488 shares Sale price: $22.50 per share Options exercised: 1,488 options +5 more

8 metrics

Shares sold 1,488 shares Open-market sale of common stock on June 22, 2026 at $22.50

Sale price $22.50 per share Price for 1,488 Evommune common shares sold on June 22, 2026

Options exercised 1,488 options Employee stock options exercised into common stock on June 22, 2026

Option strike price $3.84 per share Exercise price for 1,488 employee stock options

Shares held after 46,403 shares Direct common stock holdings following transactions on June 22, 2026

Options remaining 27,842 options Employee stock options outstanding after the June 22, 2026 exercise

Option expiration May 11, 2033 Expiration date for the employee stock option grant

10b5-1 plan adoption February 27, 2026 Date Jeegar Patel adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Buy), derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Buy) financial

"Employee Stock Option (Right to Buy) listed as a derivative security with underlying common stock."

derivative security financial

"Transaction code "M" is described as Exercise or conversion of derivative security."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Evommune (EVMN) report for Jeegar Patel?

Evommune reported that Chief Scientific Officer Jeegar Pravinkumar Patel exercised 1,488 employee stock options at $3.84 per share and sold 1,488 common shares at $22.50 per share on June 22, 2026, in an open-market transaction.

How many Evommune (EVMN) shares does Jeegar Patel hold after this Form 4?

After the June 22, 2026 transactions, Jeegar Pravinkumar Patel directly holds 46,403 shares of Evommune common stock. He also retains 27,842 employee stock options that continue to vest over time and are scheduled to expire on May 11, 2033.

At what prices did Jeegar Patel exercise and sell Evommune (EVMN) shares?

On June 22, 2026, Jeegar Pravinkumar Patel exercised 1,488 employee stock options at a strike price of $3.84 per share and sold 1,488 Evommune common shares in the open market at $22.50 per share, according to the Form 4 filing.

Was the Evommune (EVMN) insider trade under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the June 22, 2026 transactions were executed under a Rule 10b5-1 trading plan that Jeegar Pravinkumar Patel adopted on February 27, 2026, meaning the trades were pre-arranged rather than timed discretionarily.

What stock options does Jeegar Patel still have at Evommune (EVMN)?

After exercising 1,488 options, Jeegar Pravinkumar Patel still holds 27,842 employee stock options. The footnotes explain these options vest over time, with installments after the first anniversary of the grant date, and they expire on May 11, 2033.

How does this Evommune (EVMN) Form 4 classify Jeegar Patel’s transactions?

The Form 4 shows an open-market sale coded “S” for 1,488 common shares and two “M” coded transactions for exercising derivative securities. Overall, the transaction summary reflects one sale and derivative exercises totaling 1,488 shares exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 08:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Jeegar Pravinkumar

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		M(1)		1,488	A	$3.84	47,891	D
Common Stock	06/22/2026		S(1)		1,488	D	$22.5	46,403	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$3.84	06/22/2026		M(1)			1,488	(2)	05/11/2033	Common Stock	1,488	$0.00	27,842	D

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)